{"id":"ap09004","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to the D2 receptor, which is involved in the regulation of movement and other functions. This can help to alleviate symptoms of certain neurological disorders.","oneSentence":"AP09004 is a drug that targets the dopamine receptor D2.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:28:34.321Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease"}]},"trialDetails":[{"nctId":"NCT00918177","phase":"PHASE2","title":"An Evaluation of the Pharmacokinetics and Pharmacodynamics of AP09004 in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Intec Pharma Ltd.","startDate":"2009-07","conditions":"Parkinson's Disease","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AP09004","genericName":"AP09004","companyName":"Intec Pharma Ltd.","companyId":"intec-pharma-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AP09004 is a drug that targets the dopamine receptor D2. Used for Parkinson's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}